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Abstract
Using data from 756 aged Caucasian subjects from the Alzheimer’s disease Neuroimaging
Initiative (ADNI) cohort, rs1512353 located on chromosome 3 was extracted from imputed
Illumina Human610-Quad BeadChip data using Plink 2.0. Linear mixed modelling in SPSS
24 tested main effects of rs1512353 on cognitive, metabolic and neurological outcomes.
Voxel-wise regression on 404 subjects with imaging data gauged associations with
baseline glucose metabolism and GM volume. Covariates included age, gender, education,
and baseline Alzheimer’s disease diagnosis. Heterozygous and homozygous subjects were
grouped together for analyses. Alpha was .05 for non-imaging and for imaging .005 and
.05 corrected at the voxel and cluster levels.
Materials	&	Methods
Results
Conclusions
This study demonstrates that common
genetic variation in the PROK2 gene may
influence brain structure but were not
directly related to common clinical or
biological markers commonly affected
during Alzheimer’s disease. These data
indicate that PROK2 gene does
significantly affect Alzheimer's disease
risk, or affect classical biomarkers of
Alzheimer's disease in the cerebrospinal
fluid, but may affect cognitive function.
Further in vitro investigation will further
assess the role of PROK2 in regulating
neuronal mitochondria that could
potentially highlight novel pathways for
therapeutic targets to treat age-related
neurodegenerative diseases.
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Genetic	Mutations	in	Prokineticin2	Affect	Grey	Matter	Volume	in	Alzheimer’s	disease	
Background	and	Objectives
Objective: To investigate how genetic
variation in the PROK2 gene affects clinical,
cognitive and neurobiological outcomes in
subjects with or without Alzheimer’s
disease (AD). Methods: PROK2 data was
imputed from an Illumina Human610-Quad
BeadChip. Linear mixed models and voxel
wise regression assessed PROK2’s
influence on cognitive, metabolic and
neurological outcomes. Results: Minor
allele carriers at rs1512353 had grey
matter (GM) volume in the anterior
cingulate gyrus, decreased glucose
metabolism in the left post central gyrus,
and lower MMSE scores. Conclusions:
Genetic variation in the PROK2 gene may
influence grey matter volume and cognitive
function among aged Caucasian adults.
Prokineticin (PROK2), a protein involved
in hypothalamic-pituitary axis regulation,
has been shown to stimulate neurons to
produce more mitochondria1 which could
be protective during Alzheimer's disease2.
The effects of functional genetic mutations
in PROK2 on clinical, and neurobiological
indices have yet to be characterized in
humans. The primary objectives of this
study was to 1) identify if genetic
mutations in PROK2 are associated with
Alzheimer's disease risk and 2) Investigate
how PROK2 genomic mutations affect
clinical and neurobiological outcomes in
aged adults across the AD spectrum.
PROK2 rs1512353 minor allele carriers versus common allele carriers had
decreased grey matter in a small cluster of 1120 voxels spanning the right and left
postcentral gyrus (Figure 1). Minor allele carriers also had decreased glucose
metabolism in a small cluster of 1340 voxels spanning the right and left anterior
cingulum (Figure 2). Similarly minor allele carriers demonstrated worse cognitive
scores on the MMSE (F=3.519, P=0.046, Figure 3).
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Figure 2: Brain regions where  
minor allele carriers had lower  
glucose metabolism compared 
to non-carriers
Figure 1: Brain regions where  
minor allele carriers had lower grey 
matter compared to non-carriers
Figure 3: Difference in MMSE 
scores according to genotype 
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